Prophylactic mastectomy in familial breast carcinoma. What do the pathologic findings learn us?

Breast Cancer Research and Treatment

Volumn 107, Issue 1, 2008, Pages 79-86

  Leunen, Karin ^a   Drijkoningen, Maria ^a   Neven, Patrick ^a   Christiaens, Maria Rose ^a   Van Ongeval, Chantal ^a   Legius, Eric ^b   Amant, Frédéric ^a   Berteloot, Patrick ^a   Vergote, Ignace ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

BRCA; Breast ovarian cancer families; Pathologic findings; Prophylactic mastectomy

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER INVASION; CANCER PREVENTION; CANCER SURGERY; CARCINOMA IN SITU; CLINICAL DECISION MAKING; CONTROLLED STUDY; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; MUTATIONAL ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURGICAL TECHNIQUE; TREATMENT INDICATION;

ADULT; BREAST NEOPLASMS; CARCINOMA; FAMILY HEALTH; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MASTECTOMY; MUTATION; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 36548999213     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9525-8     Document Type: Article

References (41)

1. Van Eycken E, De Wever N (2006) Cancer incidence and Survival in Flanders, 2000-2001. Flemish Cancer Registry Network, VLK, Brussels
2. Sant M, Francisci S, Capocaccia R, Verdecchia A, Allemani C, Berrino F (2006) Time trends of breast cancer survival in Europe in relation to incidence and mortality. Int J Cancer 119(10):2417-2222
3. Mc Clain MR, Palomaki GE, Nathanson KL, Haddow JE (2005) Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: public health implications. Genet Med 7:28-33
4. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W et al. (1994) A strong candidate for the breast and ovaria cancer susceptibility gene BRCA1. Science 266(5182):66-71
5. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378(6559):789-92
6. Ford D, Easton DF, Stratton M et al. (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families: the Breast Cancer Linkage Consortium. Am J Hum Genet 62:676-689
7. Struewing JP, Hartge P, Wacholder S et al. (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401-1408
8. Antoniou A, Pharoah PD, Narod S et al. (2003) Average risks of breast and ovarian cancer associated with BRCA1 of BRCA2 mutation detected in case Series unselected for family history: a combined analysis of 22 studies. Am H Hum Genet 72:1117-1130
9. Hartmann LC, Schaid KJ, Woods JE et al. (1999) Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340:77-84
10. Meijers-Heijboer H, van Geel B, van Putten WL et al. (2001) Breast cancer after prophylactic bilateral mastectomy in omen with a BRCA1 or BRCA2 mutation. N Engl J Med 345:159-164
11. Rebbeck TR, Friebel T, Lynch HT (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol 22:1055-1062
12. Calderon-Margalit R, Paltiel O (2004) Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature. Int J cancer 112:357-364
13. Rosen P, Groshen S, Kinne D, Hellman S (1989) Contralateral breast carcinoma: an assessment of risk and prognosis in stage I (T1N0M0) and stage II (T1N1M0) patients with 20 year follow-up. Surgery 5:904-910
14. Newman LA, Kuerer HM, Hung KK, Vlastos G, Ames FC, Ross MI, Singletary SE (2000) Prophylactic mastectomy. J Am Coll Surg 191(3):322-329
15. Scarff Rw, Torloni H (1968) Histological typing of breast tumors. International histological classification of tumors. World Health Org 2(2):13-20
16. Elston CW, Ellis IO (1991) Pathologic prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403-410
17. Scott CI, Iorgulescu DG, Thorne HJ, Henderson MA, Philips KA (2003) Clinical, pathologic and genetic features of women at high familial risk of breast cancer undergoing prophylactic mastectomy. Clin Genet 64:111-121
18. Khurana KK, Loosmann A, Numann PJ, Khan SA (2000) Prophylactic mastectomy. Pathologic findings in high-risk patients. Arch Pathol Lab Med 124:378-381
19. Hoogerbrugge N, Bul P, Bonenkamp JJ et al. (2006) Numerous high-risk epithelial lesions in familial breast cancer. Eur J Cancer
20. Van de Groep P, Bouter A, van der Zanden R et al. (2006) Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data. J Clin Pahtol 59:611-617
21. Honrado E, Osorio A, Palacios J, Benitez J (2006) Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations. Oncogene 25:5837-5845
22. Sun CC, Lenoir G, Lynch H, Narod SA (1996) In-situ breast cancer and BRCA1[letter]. Lancet 348:1098
23. Jacquemeir J, Eisinger F, Guinebretier JM, Stoppa-Lyonnet D, Sobol H (1996) Intraductal component and BRCA1-associated breast cancer [letter]. Lancet 348:1098
24. Adam C, Reynolds C, Soderberg CL et al. (2003) Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers. Cancer 97:1-11
25. Rodriguez-Pinilla SM, Sarrio D, Honrado E, Hardisson D, Calero F, Benitez J, Palacios J (2006) Prognostic significance of basal-like photype and Fascin expression in Node negative invasive breast carcinomas. Clin Cancer Res 12(5):1533-1539
26. Rodriguez-Pinilla SM, Sarrio D, Honrado E et al. (2006) Prognostic Significance of basal like phenotyp and fasin expresión in node-negative invasive breast carcinomas. Clin Caner Res 12(5):1533-1539
27. Honrado E, Benitez J, Palacios J (2006) Histopathology of BRCA1- and BRCA2-associated breast cancer. Crit rev oncol hematol 59:27-39
28. Pierce LJ, Levin AM, Rebbeck TR et al. (2006) Ten-Year Multi-institutional results of breast conserving surgery and radiothearapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 24:2437-2443
29. Turner BC, Harrold E, Matloff et al. (1999) BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations. J Clin Oncol 17:3017-3024
30. Robson M, Svahn T, McCormick B, Borgen P, Hudis CA, Norton L, Offit K (2005) Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2. Cancer 103:44-51
31. Haffty BG, Harrold E, Khan AJ et al (2002) Outcome of conservatively managed early onset breast cancer by BRCA1/2 status. Lancet 359:1471-1477
32. Rebbeck RT, Lynch HT, Neuhausen SL et al. (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616-1622
33. Kramer JL, Velaquez IA, Chen BE, Rosenberg PS, Struewing JP, Greene MH (2005) Prophylactic oophorectomy reduces breast cancer penetrance during prospective long-term follow-up of BRCA1 mutation carriers. J Clin Oncol 23(34):8629-8635
34. Kauff ND, Brogi E, Scheuer L et al. (2003) Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations. Cancer 97:1601-1608
35. CIS of the breast, Silverstein MJ, Baril C (2002) Cancer of the breast. Donegan & Spratt. 5th edition
36. Margenthaler JA, Duke D, Monsees BS, Barton P, Clark C, Dietz JR (2006) Correlation between core biopsy and excional biopsy in breast highr-risk lesions. Am J Surg 192:534-537
37. Kuhl KC, Schrading S, Leutner CC et al. (2006) Mammography, breast ultrasound and magnetic resonance imaging for surveillance of women at high famila risk for breast cancer. J Clin Oncol 23:8469-8476
38. Kauff ND, Satagopan JM, Robson ME et al. (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609-1615
39. Olson JE, Sellers TA, Iturria SJ, Hartmann LC. (2004) Bilateral oophorectomy and breast cancer risk reduction among women with a family history. Cancer detect prev 28:357-360
40. Rebbeck TR (2002) Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. Eur J Cancer 38(S6):S15-S17
41. Eisen A, Lubinski J, Klijn J et al. (2005) Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 23(30):749-846